No items found.
PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
We are very excited to announce that MultiplexDX has won the prestigious Junior Chamber International (JCI) Creative Young Entrepreneur Award 2018 as well as two special prizes: the BMW Innovation Award and the J&T Bank Prize for Economics. The role of the competition, known as the CYEA, is to appreciate young, creative, and innovative entrepreneurs who have achieved success in their business.
Dr. Pavol Cekan and the MultiplexDX team have been working for several years to develop their revolutionary technology for oncology patients. The company aims to eliminate cancer misdiagnosis by launching a 100% accurate, quantitative and accessible diagnostic test based on the cross-validation approach.
Dr. Peter Kilian, Founder and COO of MultiplexDX, comments:
“We thank the jury, sponsors and everybody who was involved in organizing this amazing competition. We hope that our success will motivate other young researchers and scientists in the field of biotechnology and biomedicine to become entrepreneurs and push more great ideas to the market!”
In his interview with JCI Slovakia, Dr. Pavol Cekan, Founder and CEO of MultiplexDX, described his journey from a professional scientist to a successful businessman, the challenges he faced, solutions he found, and how MultiplexDX eventually turned into “the emerging biotechnology star of Central Europe”!
The JCI Creative Young Entrepreneur Award (CYEA) was launched internationally in 2005 by Junior Chamber International–the largest young person organization in the world–to recognize, honor, and celebrate exceptional young entrepreneurs and the role of creativity in their success. Winners of JCI CYEA have the chance to network, exchange business ideas, and explore business creativity with other winners worldwide. Recognition through JCI CYEA not only increases the credibility of the nominee’s organization but also boosts creativity and innovation in the industry. This benefits multiple organizations as it elevates the reputation of the entire industry and indirectly creates opportunities for other young entrepreneurs.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.